Spark Therapeutics, Inc.
DelistedCIK 1609351fmd_1EK5ENPEPDX3FNZV6YHZG5G5EXManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2014 to Sep 30, 2019, 23 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|
| Total revenues | 1 | 22 | 20 | 12 | 65 |
| Net interest income | 0 | 0 | 2 | 4 | 10 |
| Research and development | 16 | 46 | 86 | 135 | 125 |
| Total operating expenses | 25 | 69 | 146 | 271 | 258 |
| Operating income | (24) | (47) | (125) | (259) | (194) |
| Interest and investment income | 0 | 0 | – | – | – |
| Other non-operating income (expense) | – | – | 0 | 0 | 110 |
| Income before taxes | – | (47) | (124) | (254) | (79) |
| Income tax expense | – | 0 | 0 | (1) | 0 |
| Net income from continuing operations | – | (47) | (124) | (253) | (79) |
| Net income | (24) | (47) | (124) | (253) | (79) |
| Net income to common shareholders | (25) | (48) | (124) | (253) | – |